| Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy | TA1126 | | |
| Concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal) | TA1124 | | |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal) | TA1125 | | |
| Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal) | TA972 | | |
| Digital technologies for managing mild to moderate symptoms of hip or knee osteoarthritis: early value assessment | HTG766 | | |
| Digital self-help for eating disorders: early value assessment | HTG768 | | |
| Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal) | TA1123 | | |
| Balloon cryoablation for Barrett's oesophagus | HTG767 | | |
| Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1122 | | |
| Acoramidis for treating transthyretin amyloidosis with cardiomyopathy | TA1121 | | |
| Suspected cancer: recognition and referral | NG12 | | |
| Avelumab with axitinib for untreated advanced renal cell carcinoma | TA1120 | | |
| Overweight and obesity management | NG246 | | |
| Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) | TA1118 | | |
| Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia | TA1119 | | |
| VA ECMO for postcardiotomy cardiogenic shock in adults | HTG762 | | |
| DMD Care UK's guideline on respiratory care: NICE review | NR2 | | |
| Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency | TA1117 | | |
| Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia | TA1116 | | |
| Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy | TA1115 | | |
| Digital platforms to support cardiac rehabilitation: early value assessment | HTG761 | | |
| Child maltreatment: when to suspect maltreatment in under 18s | CG89 | | |
| Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma | TA1113 | | |
| Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1114 | | |
| Suspected sepsis in pregnant or recently pregnant people: recognition, diagnosis and early management | NG255 | | |
| Suspected sepsis in people aged 16 or over: recognition, assessment and early management | NG253 | | |
| Suspected sepsis in under 16s: recognition, diagnosis and early management | NG254 | | |
| Suspected sepsis in over 16s | QS213 | | |
| Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer | TA1110 | | |
| Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal) | TA1111 | | |
| Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal) | TA1112 | | |
| Intrapartum care | NG235 | | |
| Low-energy contact X-ray brachytherapy for rectal cancer | HTG763 | | |
| Fetal monitoring in labour | NG229 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA1109 | | |
| Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer | TA1108 | | |
| Cabotegravir for preventing HIV-1 in adults and young people | TA1106 | | |
| Delgocitinib for treating moderate to severe chronic hand eczema | TA1107 | | |
| Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) | TA1102 | | |
| Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal) | TA1104 | | |
| Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal) | TA1105 | | |
| VA ECMO for severe acute heart failure in adults | HTG764 | | |
| VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest | HTG765 | | |
| Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor | TA1103 | | |
| Rehabilitation for chronic neurological disorders including acquired brain injury | NG252 | | |
| Head injury | QS74 | | |
| Artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures: early value assessment | HTG760 | | |
| Sparsentan for treating primary IgA nephropathy | TA1074 | | |
| Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over | TA1101 | | |
| Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy | TA1099 | | |
| Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal) | TA1100 | | |
| HIV testing: increasing uptake among people who may have undiagnosed HIV | NG60 | | |
| Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable | TA1098 | | |
| Atopic eczema in under 12s: diagnosis and management | CG57 | | |
| Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment | HTG718 | | |
| Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable | TA1097 | | |
| DMD Care UK's guideline on cardiac care of children with dystrophinopathy and females carrying DMD-gene variations: NICE review | NR1 | | |
| Chronic heart failure in adults: diagnosis and management | NG106 | | |
| Chronic heart failure in adults | QS9 | | |
| Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis | TA1096 | | |
| Bipolar disorder: assessment and management | CG185 | | |
| Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management | NG237 | | |
| Pneumonia: diagnosis and management | NG250 | | |
| Pneumonia: diagnosis and management | QS110 | | |
| Tirzepatide for managing overweight and obesity | TA1026 | | |
| Tirzepatide for treating type 2 diabetes | TA924 | | |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over | TA1093 | | |
| Guselkumab for treating moderately to severely active ulcerative colitis | TA1094 | | |
| Guselkumab for previously treated moderately to severely active Crohn's disease | TA1095 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer | TA1092 | | |
| Compression products for treating venous leg ulcers: late-stage assessment | HTG758 | | |
| Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment | HTG759 | | |
| Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: late-stage assessment | HTG757 | | |
| Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments | TA1091 | | |
| Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma | TA1090 | | |
| Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over | TA1088 | | |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal) | TA1089 | | |
| Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence | TA1086 | | |
| Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen | TA1087 | | |
| Overweight and obesity management | QS212 | | |
| Single-step scaffold insertion for repairing symptomatic chondral knee defects | HTG728 | | |
| Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over | TA1085 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments: early value assessment | HTG756 | | |
| Cardiovascular risk assessment and lipid modification | QS100 | | |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal) | TA1082 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal) | TA1083 | | |
| Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal) | TA1084 | | |
| Fruquintinib for previously treated metastatic colorectal cancer | TA1079 | | |
| Zanubrutinib for treating relapsed or refractory mantle cell lymphoma | TA1081 | | |
| Mirikizumab for previously treated moderately to severely active Crohn's disease | TA1080 | | |
| One-piece closed bags for colostomies: late-stage assessment | HTG754 | | |
| Pulsed-field ablation for atrial fibrillation | HTG755 | | |
| Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment | HTG753 | | |
| Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal) | TA1076 | | |
| Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA1077 | | |
| Dapagliflozin for treating chronic kidney disease | TA1075 | | |
| Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) | TA1078 | | |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies | TA1073 | | |
| Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation | HTG752 | | |
| Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1071 | | |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA1072 | | |
| Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment | HTG751 | | |
| Spesolimab for treating generalised pustular psoriasis flares | TA1070 | | |
| Targeted muscle reinnervation for managing limb amputation pain | HTG750 | | |
| Caesarean birth | NG192 | | |
| Efgartigimod for treating antibody-positive generalised myasthenia gravis | TA1069 | | |
| Linzagolix for treating symptoms of endometriosis | TA1067 | | |
| Headaches in over 12s: diagnosis and management | CG150 | | |
| Somapacitan for treating growth hormone deficiency in people 3 to 17 years | TA1066 | | |
| Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | HTG749 | | |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) | TA1068 | | |
| Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA1065 | | |
| Abortion care | NG140 | | |
| Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA1064 | | |
| Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | TA1063 | | |
| Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor | TA1062 | | |
| Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | TA1060 | | |
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | TA1059 | | |
| Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment | HTG748 | | |
| Omaveloxolone for treating Friedreich's ataxia in people 16 years and over (terminated appraisal) | TA1061 | | |
| Drug-eluting stents for treating coronary artery disease: late-stage assessment | HTG747 | | |
| COVID-19 rapid guideline: managing COVID-19 | NG191 | | |
| Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 | TA878 | | |
| Artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway: early value assessment | HTG746 | | |
| Slide sheets for moving or repositioning a person: late-stage assessment | HTG745 | | |
| Falls: assessment and prevention in older people and in people 50 and over at higher risk | NG249 | | |
| Falls | QS86 | | |
| Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over | HST33 | | |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal) | TA1058 | | |
| Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour | HTG744 | | |
| Robot-assisted surgery for soft tissue procedures: early value assessment | HTG742 | | |
| Robot-assisted surgery for orthopaedic procedures: early value assessment | HTG743 | | |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA1055 | | |
| Molnupiravir for treating COVID-19 | TA1056 | | |
| Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | TA1057 | | |
| Cladribine for treating active relapsing forms of multiple sclerosis | TA1053 | | |
| Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over | TA1054 | | |
| Early and locally advanced breast cancer: diagnosis and management | NG101 | | |
| Burosumab for treating X-linked hypophosphataemia in children and young people | HST8 | | |
| Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B | HST32 | | |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over | TA1051 | | |
| Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal) | TA1052 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable | TA1048 | | |
| Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | TA1049 | | |
| Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over | TA1050 | | |
| Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) | TA1047 | | |
| Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma | TA1046 | | |
| Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertension | HTG741 | | |
| 12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites | TA1045 | | |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection | TA1043 | | |
| Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over | TA1044 | | |
| Advanced breast cancer: diagnosis and treatment | CG81 | | |
| Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer | TA1041 | | |
| Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer | TA1042 | | |
| Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy | TA1040 | | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over | TA1033 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over | TA1038 | | |
| Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over | TA1039 | | |
| Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment | HTG696 | | |
| Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment | TA1036 | | |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer | TA1037 | | |
| Ovarian cancer | QS18 | | |
| Intravascular lithotripsy to treat calcified coronary arteries during percutaneous coronary intervention | HTG740 | | |
| Tobacco: preventing uptake, promoting quitting and treating dependence | NG209 | | |
| Epilepsies in children, young people and adults | NG217 | | |
| Gambling-related harms: identification, assessment and management | NG248 | | |
| Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease | TA1035 | | |
| Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) | TA1032 | | |
| Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours | TA1034 | | |
| Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over | TA1031 | | |
| Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years | NG247 | | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal) | TA1028 | | |
| Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) | TA1029 | | |
| Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1030 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment | HTG739 | | |
| Digitally enabled therapies for adults with depression: early value assessment | HTG675 | | |
| Tebentafusp for treating advanced uveal melanoma | TA1027 | | |
| Electrically stimulated intravesical therapy for interstitial cystitis or overactive bladder in adults | HTG738 | | |
| Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia | HTG737 | | |
| Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome | HTG735 | | |
| Ublituximab for treating relapsing multiple sclerosis | TA1025 | | |
| MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's | HTG733 | | |
| MRI-guided focused ultrasound subthalamotomy for treating Parkinson's | HTG734 | | |
| Direct skeletal fixation of limb prostheses using an intraosseous transcutaneous implant | HTG732 | | |
| Urinary tract infection (recurrent): antimicrobial prescribing | NG112 | | |
| Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1023 | | |
| Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) | TA1024 | | |
| Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer | TA1021 | | |
| Bevacizumab gamma for treating wet age-related macular degeneration | TA1022 | | |
| Meningitis (bacterial) and meningococcal disease | QS19 | | |
| Asthma pathway (BTS, NICE, SIGN) | NG244 | | |
| Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | NG245 | | |
| Eplontersen for treating hereditary transthyretin-related amyloidosis | TA1020 | | |
| Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer | TA1017 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA1018 | | |
| Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over | TA1019 | | |
| Elafibranor for previously treated primary biliary cholangitis | TA1016 | | |
| Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction | HTG731 | | |
| Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments | TA1015 | | |
| Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer | TA1014 | | |
| Endometriosis: diagnosis and management | NG73 | | |
| Menopause: identification and management | NG23 | | |
| Avapritinib for treating advanced systemic mastocytosis | TA1012 | | |
| Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices | HTG730 | | |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia | TA1013 | | |
| Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria | TA1010 | | |
| Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) | HTG729 | | |
| Acute kidney injury: prevention, detection and management | NG148 | | |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease | TA1011 | | |
| Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension | TA1009 | | |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments | TA1008 | | |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | TA1007 | | |
| Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal) | TA1006 | | |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over | TA1002 | | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over | TA1003 | | |
| Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion | TA1004 | | |
| Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA1005 | | |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria | TA1000 | | |
| Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment | TA1001 | | |
| Vibegron for treating symptoms of overactive bladder syndrome | TA999 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma | TA997 | | |
| Adrenal insufficiency: identification and management | NG243 | | |
| Risankizumab for treating moderately to severely active ulcerative colitis | TA998 | | |
| Phrenic nerve pacing for congenital central hypoventilation syndrome | HTG725 | | |
| Caval valve implantation for tricuspid regurgitation | HTG726 | | |
| Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury | HTG727 | | |
| Relugolix for treating hormone-sensitive prostate cancer | TA995 | | |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids | TA996 | | |
| Diabetic retinopathy: management and monitoring | NG242 | | |
| Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) | TA994 | | |
| Abaloparatide for treating osteoporosis after menopause | TA991 | | |
| Burosumab for treating X-linked hypophosphataemia in adults | TA993 | | |
| CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack | HTG724 | | |
| Anaphylaxis | QS119 | | |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy | TA992 | | |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis | TA988 | | |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B | TA989 | | |
| Tenecteplase for treating acute ischaemic stroke | TA990 | | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal) | TA987 | | |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over | TA986 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Minimally invasive percutaneous surgical techniques with internal fixation for correcting hallux valgus | HTG723 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA984 | | |
| Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) | TA982 | | |
| Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma | TA983 | | |
| Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation | TA979 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) | TA980 | | |
| Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA976 | | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over | TA977 | | |
| Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal) | TA978 | | |
| Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome | HST31 | | |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis | TA312 | | |
| Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis | TA127 | | |
| Cladribine for treating relapsing–remitting multiple sclerosis | TA616 | | |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia | TA298 | | |
| Ranibizumab and pegaptanib for the treatment of age-related macular degeneration | TA155 | | |
| Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion | TA283 | | |
| Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver | HTG720 | | |
| Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes | HTG721 | | |
| Image-guided percutaneous laser ablation for primary and secondary liver tumours | HTG722 | | |
| Atogepant for preventing migraine | TA973 | | |
| Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma | TA974 | | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under | TA975 | | |
| Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer | HTG719 | | |
| Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments | TA970 | | |
| Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | | |
| Artificial intelligence (AI)-derived software to help clinical decision making in stroke | HTG708 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma | TA540 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over | TA967 | | |
| Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) | TA969 | | |
| Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA968 | | |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) | TA966 | | |
| Lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema | HTG717 | | |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma | TA964 | | |
| Twin and triplet pregnancy | NG137 | | |
| Kurin Lock for blood culture collection | HTG715 | | |
| GaitSmart rehabilitation exercise programme for gait and mobility issues | HTG716 | | |
| Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer | HTG714 | | |
| Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal) | TA961 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy | TA962 | | |
| Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) | TA965 | | |
| Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal) | TA960 | | |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over | TA958 | | |
| Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis | TA959 | | |
| Desflurane for maintenance of anaesthesia | ES41 | | |
| Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment | HTG713 | | |
| Ovarian cancer: identifying and managing familial and genetic risk | NG241 | | |
| Momelotinib for treating myelofibrosis-related splenomegaly or symptoms | TA957 | | |
| Neonatal infection: antibiotics for prevention and treatment | NG195 | | |
| Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management | NG240 | | |
| ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment | HTG664 | | |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema | TA953 | | |
| Dupilumab for treating moderate to severe prurigo nodularis | TA955 | | |
| Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over | TA956 | | |
| Lung cancer: diagnosis and management | NG122 | | |
| Vitamin B12 deficiency in over 16s: diagnosis and management | NG239 | | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA954 | | |
| Digital technologies for delivering multidisciplinary weight-management services: early value assessment | HTG700 | | |
| Digital technologies for managing non-specific low back pain: early value assessment | HTG712 | | |
| Endoscopic sleeve gastroplasty for obesity | HTG711 | | |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations | TA952 | | |
| Tuberculosis | NG33 | | |
| Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over | TA949 | | |
| Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over | TA950 | | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer | TA951 | | |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments | TA947 | | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments | TA948 | | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) | TA945 | | |
| Devices for remote monitoring of Parkinson's disease | HTG657 | | |
| COVID-19 rapid guideline: managing the long-term effects of COVID-19 | NG188 | | |
| Skin cancer | QS130 | | |
| Neonatal infection | QS75 | | |
| Pharyngeal electrical stimulation for neurogenic dysphagia | HTG709 | | |
| Temperature control to improve neurological outcomes after cardiac arrest | HTG710 | | |
| Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer | TA946 | | |
| Sebelipase alfa for treating Wolman disease | HST30 | | |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer | TA944 | | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | HTG707 | | |
| Epilepsies in children, young people and adults | QS211 | | |
| Ravulizumab for treating generalised myasthenia gravis (terminated appraisal) | TA940 | | |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal) | TA941 | | |
| Empagliflozin for treating chronic kidney disease | TA942 | | |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | TA943 | | |
| Risdiplam for treating spinal muscular atrophy | TA755 | | |
| Cardiovascular disease: risk assessment and reduction, including lipid modification | NG238 | | |
| Transition from children's to adults' services | QS140 | | |
| Digitally enabled therapies for adults with anxiety disorders: early value assessment | HTG676 | | |
| Middle meningeal artery embolisation for chronic subdural haematomas | HTG706 | | |
| Velmanase alfa for treating alpha-mannosidosis | HST29 | | |
| Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer | TA939 | | |
| Acne vulgaris: management | NG198 | | |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) | TA938 | | |
| Secukinumab for treating moderate to severe hidradenitis suppurativa | TA935 | | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal) | TA936 | | |
| Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal) | TA933 | | |
| Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms | TA934 | | |
| Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism | HTG705 | | |
| Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal) | TA932 | | |
| Zanubrutinib for treating chronic lymphocytic leukaemia | TA931 | | |
| Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis | HTG704 | | |
| Transient loss of consciousness ('blackouts') in over 16s | CG109 | | |
| Hypertension in adults: diagnosis and management | NG136 | | |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments | TA930 | | |
| Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment | HTG701 | | |
| Biodegradable subacromial spacer insertion for rotator cuff tears | HTG702 | | |
| Extracorporeal carbon dioxide removal for acute respiratory failure | HTG703 | | |
| Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer | CG164 | | |
| Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine | TA928 | | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA929 | | |
| Jaundice in newborn babies under 28 days | CG98 | | |
| Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home) | QS210 | | |
| Ranibizumab for treating diabetic macular oedema | TA274 | | |
| Mirikizumab for treating moderately to severely active ulcerative colitis | TA925 | | |
| Baricitinib for treating severe alopecia areata | TA926 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable | TA917 | | |
| Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions | HTG699 | | |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal) | TA923 | | |
| Stroke rehabilitation in adults | NG236 | | |
| Rimegepant for treating migraine | TA919 | | |
| Tofacitinib for treating active ankylosing spondylitis | TA920 | | |
| Ruxolitinib for treating polycythaemia vera | TA921 | | |
| Daridorexant for treating long-term insomnia | TA922 | | |
| Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | HTG698 | | |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments | TA927 | | |
| Thyroid disease: assessment and management | NG145 | | |
| Virtual ward platform technologies for acute respiratory infections: early value assessment | HTG697 | | |
| Bimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA918 | | |
| Pegunigalsidase alfa for treating Fabry disease | TA915 | | |
| Bimekizumab for treating active psoriatic arthritis | TA916 | | |
| Ovarian cancer: recognition and initial management | CG122 | | |
| Urinary incontinence in neurological disease: assessment and management | CG148 | | |
| Suspected neurological conditions: recognition and referral | NG127 | | |
| Hearing loss in adults: assessment and management | NG98 | | |
| COVID-19 rapid guideline: haematopoietic stem cell transplantation | NG164 | | |
| Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment | HTG695 | | |
| KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment | HTG694 | | |
| Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment | HTG693 | | |
| Birch bark extract for treating epidermolysis bullosa | HST28 | | |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency | TA914 | | |
| Chronic obstructive pulmonary disease in adults | QS10 | | |
| Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG691 | | |
| Cryotherapy for chronic rhinitis | HTG692 | | |
| Cirrhosis in over 16s: assessment and management | NG50 | | |
| Spinal metastases and metastatic spinal cord compression | NG234 | | |
| Spinal metastases and metastatic spinal cord compression | QS56 | | |
| Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy | TA913 | | |
| Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment | HTG660 | | |
| Semaglutide for managing overweight and obesity | TA875 | | |
| Otitis media with effusion in under 12s | NG233 | | |
| Quantitative faecal immunochemical testing to guide colorectal cancer pathway referral in primary care | HTG690 | | |
| Ectopic pregnancy and miscarriage: diagnosis and initial management | NG126 | | |
| Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease | TA912 | | |
| Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment | HTG665 | | |
| Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease | HTG689 | | |
| Venous thromboembolic diseases: diagnosis, management and thrombophilia testing | NG158 | | |
| Afamelanotide for treating erythropoietic protoporphyria | HST27 | | |
| Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer | TA911 | | |
| KardiaMobile for detecting atrial fibrillation | HTG606 | | |
| Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal) | TA910 | | |
| Alcohol-use disorders: diagnosis and management | QS11 | | |
| Artificial intelligence (AI)-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan images | HTG687 | | |
| Rimegepant for preventing migraine | TA906 | | |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy | TA908 | | |
| Irreversible electroporation for treating prostate cancer | HTG688 | | |
| Oesophago-gastric cancer: assessment and management in adults | NG83 | | |
| Depression in adults | QS8 | | |
| Deucravacitinib for treating moderate to severe plaque psoriasis | TA907 | | |
| Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention | HTG685 | | |
| Radiofrequency denervation for osteoarthritic knee pain | HTG686 | | |
| Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option | HTG683 | | |
| Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people | HTG684 | | |
| Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction | TA902 | | |
| Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer | TA903 | | |
| Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer | TA904 | | |
| Upadacitinib for previously treated moderately to severely active Crohn's disease | TA905 | | |
| MiraQ cardiac TTFM with high-frequency probe for assessing graft flow during coronary artery bypass graft surgery | MIB323 | | |
| Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal) | TA901 | | |
| Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer | TA898 | | |
| Tixagevimab plus cilgavimab for preventing COVID-19 | TA900 | | |
| YOURmeds for medication support in long-term conditions | MIB289 | | |
| FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care | HTG682 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over | TA893 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma | TA894 | | |
| Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy | TA895 | | |
| Bulevirtide for treating chronic hepatitis D | TA896 | | |
| Proov Confirm for ovulation confirmation | MIB322 | | |
| Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) | TA899 | | |
| Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma | TA897 | | |
| Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer | HTG681 | | |
| Transperineal biopsy for diagnosing prostate cancer | HTG680 | | |
| Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia | TA891 | | |
| Mosunetuzumab for treating relapsed or refractory follicular lymphoma | TA892 | | |
| MRI fusion biopsy systems for diagnosing prostate cancer | HTG678 | | |
| Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcers | HTG677 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries | HTG679 | | |
| Head injury: assessment and early management | NG232 | | |
| Risankizumab for previously treated moderately to severely active Crohn's disease | TA888 | | |
| Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA889 | | |
| Difelikefalin for treating pruritus in people having haemodialysis | TA890 | | |
| Diabetes (type 1 and type 2) in children and young people: diagnosis and management | NG18 | | |
| Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy | TA886 | | |
| Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer | TA887 | | |
| Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment | HTG674 | | |
| Voclosporin with mycophenolate mofetil for treating lupus nephritis | TA882 | | |
| Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma | TA883 | | |
| Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal) | TA884 | | |
| Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments | TA881 | | |
| Metastatic malignant disease of unknown primary origin in adults: diagnosis and management | CG104 | | |
| Fasciotens for abdominal wall closure | MIB321 | | |
| Tezepelumab for treating severe asthma | TA880 | | |
| Lumasiran for treating primary hyperoxaluria type 1 | HST25 | | |
| Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency | HST26 | | |
| Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy | HST24 | | |
| Onasemnogene abeparvovec for treating spinal muscular atrophy | HST15 | | |
| Daytime intraoral neuromuscular electrical tongue stimulation using a removable device for obstructive sleep apnoea | HTG672 | | |
| Endoscopic ultrasound-guided biliary drainage for biliary obstruction | HTG673 | | |
| Hypertension in pregnancy: diagnosis and management | NG133 | | |
| AposHealth for knee osteoarthritis | HTG671 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) | TA879 | | |
| Percutaneous thoracic duct embolisation for persistent chyle leak | HTG666 | | |
| Focal therapy using high-intensity focused ultrasound for localised prostate cancer | HTG667 | | |
| Radiofrequency ablation for palliation of painful spinal metastases | HTG669 | | |
| Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases | HTG670 | | |
| Maximal cytoreductive surgery for advanced ovarian cancer | HTG668 | | |
| UrgoStart for treating diabetic foot ulcers and leg ulcers | HTG502 | | |
| Macimorelin for diagnosing growth hormone deficiency | MIB320 | | |
| Acute kidney injury | QS76 | | |
| Finerenone for treating chronic kidney disease in type 2 diabetes | TA877 | | |
| Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer | TA876 | | |
| CaRi-Heart for predicting cardiac risk in suspected coronary artery disease: early value assessment | HTG663 | | |
| Type 1 diabetes in adults | QS208 | | |
| Type 2 diabetes in adults | QS209 | | |
| Asfotase alfa for treating paediatric-onset hypophosphatasia | HST23 | | |
| Eptinezumab for preventing migraine | TA871 | | |
| Cannabidiol for treating seizures caused by tuberous sclerosis complex | TA873 | | |
| Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma | TA874 | | |
| Endoluminal gastroplication for gastro-oesophageal reflux disease | HTG661 | | |
| Percutaneous transluminal renal sympathetic denervation for resistant hypertension | HTG662 | | |
| Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies | TA872 | | |
| Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene | HST22 | | |
| Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma | TA870 | | |
| LIVERFASt for assessing and monitoring liver fibrosis, activity and steatosis | MIB317 | | |
| Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) | TA867 | | |
| Urinary tract infections in adults | QS90 | | |
| Vutrisiran for treating hereditary transthyretin-related amyloidosis | TA868 | | |
| Ambu aScope 4 RhinoLaryngo for visualising upper airways during rhinolaryngoscopy | MIB316 | | |
| Antenatal care | QS22 | | |
| Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | NG231 | | |
| Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma | TA865 | | |
| Regorafenib for previously treated metastatic colorectal cancer | TA866 | | |
| Transvenous obliteration for gastric varices | HTG658 | | |
| Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer | HTG659 | | |
| Upadacitinib for treating active non-radiographic axial spondyloarthritis | TA861 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | | |
| Somatrogon for treating growth disturbance in children and young people aged 3 years and over | TA863 | | |
| Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted | TA864 | | |
| Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia | MIB315 | | |
| Delirium: prevention, diagnosis and management in hospital and long-term care | CG103 | | |
| Maribavir for treating refractory cytomegalovirus infection after transplant | TA860 | | |
| Ambu aScope 4 Broncho for routine diagnostic and therapeutic bronchoscopy | MIB314 | | |
| Trabeculectomy with a biodegradable collagen matrix implant for glaucoma | HTG656 | | |
| Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) | TA859 | | |
| Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education | NG213 | | |
| MRI-based technologies for assessing non-alcoholic fatty liver disease | HTG655 | | |
| Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma | TA857 | | |
| Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma | TA858 | | |
| Transcutaneous electrical stimulation of the trigeminal nerve for ADHD | HTG653 | | |
| Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease | HTG654 | | |
| PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis | MIB313 | | |
| Diabetes in pregnancy | QS109 | | |
| Hip fracture: management | CG124 | | |
| Hip fracture in adults | QS16 | | |
| Upadacitinib for treating moderately to severely active ulcerative colitis | TA856 | | |
| Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain | HTG652 | | |
| Thyroid cancer: assessment and management | NG230 | | |
| Tobacco: treating dependence | QS207 | | |
| Avatrombopag for treating primary chronic immune thrombocytopenia | TA853 | | |
| Cabozantinib for previously treated advanced hepatocellular carcinoma | TA849 | | |
| Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy | TA850 | | |
| Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | TA851 | | |
| Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments | TA852 | | |
| Esketamine nasal spray for treatment-resistant depression | TA854 | | |
| PromarkerD for predicting the risk of diabetic kidney disease in people with type 2 diabetes | MIB312 | | |
| Memokath 051 Ureter stent for ureteric obstruction | HTG651 | | |
| Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) | TA848 | | |
| Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) | TA845 | | |
| Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) | TA846 | | |
| Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA847 | | |
| Optilume for treating recurrent bulbar urethral strictures | HTG649 | | |
| GreenLight XPS for treating benign prostatic hyperplasia | HTG650 | | |
| Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) | TA843 | | |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) | TA844 | | |
| Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and management | NG228 | | |
| Fractures (complex): assessment and management | NG37 | | |
| Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis | HTG648 | | |
| Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA841 | | |
| Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal) | TA842 | | |
| Ab interno canaloplasty for open-angle glaucoma | HTG647 | | |
| Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids
(terminated appraisal) | TA840 | | |
| Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules | HTG646 | | |
| Advocacy services for adults with health and social care needs | NG227 | | |
| Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder | HTG645 | | |
| Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) | TA838 | | |
| Digital technologies for the detection of melanoma | MIB311 | | |
| Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA836 | | |
| Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | TA837 | | |
| Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine | HTG643 | | |
| YAG laser vitreolysis for symptomatic vitreous floaters | HTG644 | | |
| Osteoarthritis in over 16s: diagnosis and management | NG226 | | |
| Osteoarthritis in over 16s | QS87 | | |
| Zanubrutinib for treating Waldenstrom's macroglobulinaemia | TA833 | | |
| Fostamatinib for treating refractory chronic immune thrombocytopenia | TA835 | | |
| Pembrolizumab for adjuvant treatment of renal cell carcinoma | TA830 | | |
| Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids | TA832 | | |
| O2matic PRO 100 for optimising oxygen treatment in respiratory conditions | MIB308 | | |
| Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy | TA827 | | |
| Ozanimod for treating moderately to severely active ulcerative colitis | TA828 | | |
| Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer | HTG642 | | |
| Signatera for detecting molecular residual disease from solid tumour cancers | MIB307 | | |
| Upadacitinib for treating active ankylosing spondylitis | TA829 | | |
| Postnatal care | QS37 | | |
| Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | HTG641 | | |
| iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia | MIB306 | | |
| Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis | TA825 | | |
| Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal) | TA826 | | |
| Neuropad for detecting preclinical diabetic peripheral neuropathy | HTG486 | | |
| Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG639 | | |
| Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause | HTG640 | | |
| Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas | CG118 | | |
| Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal) | TA822 | | |
| Dexamethasone intravitreal implant for treating diabetic macular oedema | TA824 | | |
| Self-harm: assessment, management and preventing recurrence | NG225 | | |
| Self‑harm | QS34 | | |
| Brolucizumab for treating diabetic macular oedema | TA820 | | |
| Faecal microbiota transplant for recurrent Clostridioides difficile infection | HTG638 | | |
| Contrast-enhanced spectral mammography for breast cancer | MIB304 | | |
| Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain | MIB305 | | |
| iFuse for treating chronic sacroiliac joint pain | HTG488 | | |
| Avalglucosidase alfa for treating Pompe disease | TA821 | | |
| Transcutaneous electrical neuromuscular stimulation for urinary incontinence | HTG636 | | |
| Superficial venous arterialisation for chronic limb threatening ischaemia | HTG637 | | |
| Focal resurfacing implants to treat articular cartilage damage in the knee | HTG635 | | |
| Type 1 diabetes in adults: diagnosis and management | NG17 | | |
| Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma | TA818 | | |
| Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies | TA819 | | |
| Cefiderocol for treating severe drug-resistant gram-negative bacterial infections | AMR2 | | |
| Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections | AMR1 | | |
| Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence | TA817 | | |
| Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | | |
| Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer | TA816 | | |
| SecurAcath for securing percutaneous catheters | HTG440 | | |
| Stockholm3 for prostate cancer screening | MIB303 | | |
| Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors | TA813 | | |
| Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis | TA814 | | |
| Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer | TA812 | | |
| Bioresorbable stent implantation to treat coronary artery disease | HTG633 | | |
| Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection | HTG634 | | |
| PLGF-based testing to help diagnose suspected preterm pre-eclampsia | HTG630 | | |
| Melanoma: assessment and management | NG14 | | |
| Urinary tract infection in under 16s: diagnosis and management | NG224 | | |
| Fever in under 5s | QS64 | | |
| Urinary tract infection in children and young people | QS36 | | |
| Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal) | TA811 | | |
| Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation | HTG631 | | |
| Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation | HTG632 | | |
| Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease | TA809 | | |
| Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence | TA810 | | |
| PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites | HTG282 | | |
| Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | | |
| Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides | TA805 | | |
| Belimumab for treating lupus nephritis (terminated appraisal) | TA806 | | |
| Roxadustat for treating symptomatic anaemia in chronic kidney disease | TA807 | | |
| ProciseDx point-of-care platform for inflammatory bowel disease | MIB302 | | |
| Fenfluramine for treating seizures associated with Dravet syndrome | TA808 | | |
| Setmelanotide for treating obesity caused by LEPR or POMC deficiency | HST21 | | |
| Social, emotional and mental wellbeing in primary and secondary education | NG223 | | |
| RespiraSense for continuously monitoring respiratory rate | MIB299 | | |
| Cyanoacrylate glue for hernia mesh fixation | MIB301 | | |
| MiraQ for assessing graft flow during coronary artery bypass graft surgery | HTG275 | | |
| Teduglutide for treating short bowel syndrome | TA804 | | |
| Type 2 diabetes in adults: management | NG28 | | |
| Depression in adults: treatment and management | NG222 | | |
| Faricimab for treating diabetic macular oedema | TA799 | | |
| Faricimab for treating wet age-related macular degeneration | TA800 | | |
| Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer | TA801 | | |
| Cemiplimab for treating advanced cutaneous squamous cell carcinoma | TA802 | | |
| Vertebral body tethering for idiopathic scoliosis in children and young people | HTG628 | | |
| Nerve graft for corneal denervation | HTG629 | | |
| Multiple sclerosis in adults: management | NG220 | | |
| Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation | TA798 | | |
| Reducing sexually transmitted infections | NG221 | | |
| Venetoclax for treating chronic lymphocytic leukaemia | TA796 | | |
| Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) | TA797 | | |
| Preterm labour and birth | NG25 | | |
| Gout: diagnosis and management | NG219 | | |
| Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) | TA793 | | |
| Diroximel fumarate for treating relapsing–remitting multiple sclerosis | TA794 | | |
| Ibrutinib for treating Waldenstrom's macroglobulinaemia | TA795 | | |
| Peristeen Plus transanal irrigation system for managing bowel dysfunction | HTG462 | | |
| Thopaz+ portable digital system for managing chest drains | HTG465 | | |
| Filgotinib for treating moderately to severely active ulcerative colitis | TA792 | | |
| Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) | HTG627 | | |
| Social work with adults experiencing complex needs | NG216 | | |
| TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) | TA790 | | |
| Romosozumab for treating severe osteoporosis | TA791 | | |
| Endoanchoring systems in endovascular aortic aneurysm repair | HTG625 | | |
| Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis | HTG626 | | |
| Sleepio to treat insomnia and insomnia symptoms | HTG624 | | |
| Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations | TA789 | | |
| Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome | HTG623 | | |
| Vaccine uptake in the general population | NG218 | | |
| Vaccine uptake in under 19s | QS145 | | |
| Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults | ES40 | | |
| Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections | ES39 | | |
| Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy | TA788 | | |
| ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions | MIB295 | | |
| Granulox for managing chronic non-healing wounds | MIB296 | | |
| Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over | HST20 | | |
| AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas | MIB294 | | |
| Bladder EpiCheck for detecting bladder cancer recurrence | MIB293 | | |
| Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | | |
| Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA787 | | |
| Liposuction for chronic lymphoedema | HTG622 | | |
| Elosulfase alfa for treating mucopolysaccharidosis type 4A | HST19 | | |
| Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults | NG215 | | |
| Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer | TA784 | | |
| Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) | TA785 | | |
| Intramedullary distraction for upper limb lengthening | HTG621 | | |
| Stroke and transient ischaemic attack in over 16s: diagnosis and initial management | NG128 | | |
| Daratumumab monotherapy for treating relapsed and refractory multiple myeloma | TA783 | | |
| Diabetes in children and young people | QS125 | | |
| UroShield for preventing catheter-associated urinary tract infections | HTG620 | | |
| Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) | HTG619 | | |
| Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer | TA781 | | |
| Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) | TA782 | | |
| icobrain ms for active relapsing–remitting multiple sclerosis | MIB291 | | |
| Joint replacement (primary): hip, knee and shoulder | QS206 | | |
| Liposuction for chronic lipoedema | HTG618 | | |
| Atidarsagene autotemcel for treating metachromatic leukodystrophy | HST18 | | |
| Nivolumab with ipilimumab for untreated advanced renal cell carcinoma | TA780 | | |
| Neonatal parenteral nutrition | QS205 | | |
| Integrated health and social care for people experiencing homelessness | NG214 | | |
| Fetal alcohol spectrum disorder | QS204 | | |
| Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | TA779 | | |
| SecurePort IV tissue adhesive for use with percutaneous catheters | MIB288 | | |
| Otitis media (acute): antimicrobial prescribing | NG91 | | |
| Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria | TA778 | | |
| Empagliflozin for treating chronic heart failure with reduced ejection fraction | TA773 | | |
| Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal) | TA774 | | |
| Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA776 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea | TA777 | | |
| Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis | HTG617 | | |
| Prontosan for treating acute and chronic wounds | HTG616 | | |
| 3C Patch for treating diabetic foot ulcers | HTG615 | | |
| Mental wellbeing at work | NG212 | | |
| Intramedullary distraction for lower limb lengthening | HTG613 | | |
| Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach | HTG612 | | |
| Endoscopic balloon dilation for subglottic or tracheal stenosis | HTG614 | | |
| Lumella point-of-care test for assessing pre-eclampsia risk | MIB287 | | |
| PredictSURE IBD and IBDX to guide treatment of Crohn's disease | HTG610 | | |
| EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules | HTG611 | | |
| Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies | TA772 | | |
| Odevixibat for treating progressive familial intrahepatic cholestasis | HST17 | | |
| The Insides System for managing intestinal failure | MIB286 | | |
| Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer | TA770 | | |
| Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) | TA771 | | |
| d-Nav insulin management app for type 2 diabetes | MIB285 | | |
| Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable | TA763 | | |
| Fremanezumab for preventing migraine | TA764 | | |
| Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable | TA765 | | |
| Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | TA766 | | |
| Ponesimod for treating relapsing–remitting multiple sclerosis | TA767 | | |
| Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | | |
| Palforzia for treating peanut allergy in children and young people | TA769 | | |
| Stereotactic radiosurgery for trigeminal neuralgia | HTG608 | | |
| Microwave ablation for primary or metastatic cancer in the lung | HTG609 | | |
| Colorectal cancer | QS20 | | |
| Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care | HTG607 | | |
| Glaucoma: diagnosis and management | NG81 | | |
| Sodium zirconium cyclosilicate for treating hyperkalaemia | TA599 | | |
| Rehabilitation after traumatic injury | NG211 | | |
| Smart Peak Flow for monitoring asthma | MIB282 | | |
| Cabotegravir with rilpivirine for treating HIV-1 | TA757 | | |
| Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy | TA758 | | |
| Prostate cancer | QS91 | | |
| Endo-SPONGE for treating low rectal anastomotic leak | HTG605 | | |
| Prostate cancer: diagnosis and management | NG131 | | |
| Colorectal cancer | NG151 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| Transanal total mesorectal excision for rectal cancer | HTG603 | | |
| Endobronchial nerve ablation for chronic obstructive pulmonary disease | HTG604 | | |
| ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | HTG602 | | |
| Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
| Urinary incontinence in women | QS77 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome | MIB281 | | |
| Brain tumours (primary) and brain metastases in over 16s | QS203 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia | MIB278 | | |
| CerebAir for continuous EEG monitoring in intensive care | MIB279 | | |
| Paige Prostate for prostate cancer | MIB280 | | |
| Synergo for non-muscle-invasive bladder cancer | HTG601 | | |
| Fever in under 5s: assessment and initial management | NG143 | | |
| Givosiran for treating acute hepatic porphyria | HST16 | | |
| Chronic kidney disease: assessment and management | NG203 | | |
| Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure | HTG599 | | |
| Coronary sinus narrowing device implantation for refractory angina | HTG600 | | |
| SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | HTG598 | | |
| Acute heart failure: diagnosis and management | CG187 | | |
| Heart valve disease presenting in adults: investigation and management | NG208 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Inducing labour | NG207 | | |
| Inducing labour | QS60 | | |
| 24/7 EEG SubQ for epilepsy | MIB277 | | |
| Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Genicular artery embolisation for pain from knee osteoarthritis | HTG595 | | |
| Laparoscopic renal denervation for loin pain haematuria syndrome | HTG596 | | |
| Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access | HTG597 | | |
| Looked-after children and young people | NG205 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | HTG594 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Lateral elbow resurfacing for arthritis | HTG591 | | |
| Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis | HTG592 | | |
| Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair | HTG593 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| OrganOx metra for liver transplant | MIB275 | | |
| Carnation Ambulatory Monitor for ambulatory detection of cardiac arrythmias | MIB276 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Workplace health: long-term sickness absence and capability to work | QS202 | | |
| End of life care for adults | QS13 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Colli-Pee for first void urine collection | MIB273 | | |
| PLASMA system with button electrode for electrovaporisation of the prostate | MIB274 | | |
| Babies, children and young people's experience of healthcare | NG204 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids | HTG590 | | |
| Magnetic resonance therapy for knee osteoarthritis | HTG588 | | |
| Laparoscopic removal of uterine fibroids with power morcellation | HTG589 | | |
| Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Antenatal care | NG201 | | |
| Venous thromboembolism in adults | QS201 | | |
| Melatonin for treating sleep disorders in adults who are blind | ES38 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Antimicrobial prescribing: delafloxacin for community-acquired pneumonia | ES37 | | |
| MMprofiler for prognostic risk classification in multiple myeloma | MIB270 | | |
| Patient Status Engine for wireless monitoring of vital signs | MIB271 | | |
| Lung texture analysis for measuring interstitial lung diseases | MIB272 | | |
| Bronchiolitis in children: diagnosis and management | NG9 | | |
| Immunoscore for predicting risk of colon cancer relapse | MIB269 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage | HTG587 | | |
| Clostridioides difficile infection: antimicrobial prescribing | NG199 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| ENDURALIFE powered CRT-D devices for treating heart failure | HTG433 | | |
| Ixekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA718 | | |
| Secukinumab for treating active non-radiographic axial spondyloarthritis | TA719 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| HealthVCF for detecting vertebral compression fractures on CT scans | MIB267 | | |
| trublood-prostate for triaging and diagnosing people with prostate cancer symptoms | MIB268 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| AI technologies for detecting diabetic retinopathy | MIB265 | | |
| Acumen IQ sensor for predicting hypotension risk | MIB266 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Atrial fibrillation: diagnosis and management | NG196 | | |
| Plus Sutures for preventing surgical site infection | HTG586 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Laser lithotripsy for difficult-to-treat bile duct stones | HTG584 | | |
| Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve | HTG585 | | |
| Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
| Shared decision making | NG197 | | |
| SYNE-COV for predicting COVID-19 outcomes | MIB264 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
| Autism spectrum disorder in under 19s: support and management | CG170 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| WoundExpress to manage lower leg wounds | MIB261 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant | HTG580 | | |
| Transvaginal laser therapy for stress urinary incontinence | HTG581 | | |
| Transvaginal laser therapy for urogenital atrophy | HTG582 | | |
| Electrohydraulic lithotripsy for difficult-to-treat bile duct stones | HTG583 | | |
| Heavy menstrual bleeding: assessment and management | NG88 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | HTG355 | | |
| HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | HTG429 | | |
| KODEX-EPD for cardiac imaging during ablation of arrhythmias | MIB260 | | |
| Permanent His-bundle pacemaker implantation for treating heart failure | HTG579 | | |
| Axonics sacral neuromodulation system for faecal incontinence | MIB259 | | |
| UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | HTG578 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma | HTG576 | | |
| Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults | HTG577 | | |
| microINR for anticoagulation therapy | MIB257 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | HTG575 | | |
| Postnatal care | NG194 | | |
| Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
| RenalSense Clarity RMS for acute kidney injury | MIB256 | | |
| Caesarean birth | QS32 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Danis stent for acute oesophageal variceal bleeding | HTG574 | | |
| Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids | HTG572 | | |
| Extracorporeal whole liver perfusion for acute liver failure | HTG573 | | |
| Sonata system for diagnostic imaging and treatment of symptomatic uterine fibroids | MIB255 | | |
| Cannabis-based medicinal products | NG144 | | |
| Supporting adult carers | QS200 | | |
| QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography | HTG571 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Erenumab for preventing migraine | TA682 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Alpha-Stim AID for anxiety disorders | HTG570 | | |
| Butterfly iQ+ for diagnostic ultrasound imaging | MIB254 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury | HTG568 | | |
| Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis | HTG569 | | |
| Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing | NG190 | | |
| Safeguarding adults in care homes | NG189 | | |
| Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis | ES35 | | |
| Metreleptin for treating lipodystrophy | HST14 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| moorLDLS-BI for burn depth assessment | MIB251 | | |
| The STAK tool for preventing and treating knee stiffness | MIB252 | | |
| PROPEL sinus implants for maintaining sinus patency after surgery | MIB253 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| URO17 for detecting bladder cancer | MIB250 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Leukomed Sorbact for preventing surgical site infection | HTG567 | | |
| DOAC Dipstick for detecting direct oral anticoagulants | MIB248 | | |
| CytoSorb for reducing risk of bleeding during cardiac surgery | MIB249 | | |
| Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal | HTG566 | | |
| Self-expanding implant insertion into the intersphincteric space for faecal incontinence | HTG564 | | |
| Minimally invasive radical hysterectomy for early stage cervical cancer | HTG565 | | |
| Accuro for guiding epidural or spinal anaesthesia | MIB245 | | |
| AcQMap for mapping the heart atria to target ablation treatment for arrhythmias | MIB246 | | |
| Abortion care | QS199 | | |
| Natural Cycles for monitoring fertility | MIB244 | | |
| Suspected neurological conditions: recognition and referral | QS198 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |
| The PLASMA system for transurethral resection and haemostasis of the prostate | HTG563 | | |
| Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections | ES32 | | |
| Optilume for anterior urethral strictures | MIB241 | | |
| Artificial intelligence in mammography | MIB242 | | |
| Artificial intelligence for analysing chest CT images | MIB243 | | |
| Pancreatitis | NG104 | | |
| Diabetes in pregnancy: management from preconception to the postnatal period | NG3 | | |
| Eating disorders: recognition and treatment | NG69 | | |
| Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma | TA666 | | |
| Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura | TA667 | | |
| ReStore Soft Exo-Suit for gait rehabilitation | MIB239 | | |
| Cytosponge for detecting abnormal cells in the oesophagus | MIB240 | | |
| Peripheral arterial disease: diagnosis and management | CG147 | | |
| Low back pain and sciatica in over 16s: assessment and management | NG59 | | |
| Upadacitinib for treating severe rheumatoid arthritis | TA665 | | |
| Liraglutide for managing overweight and obesity | TA664 | | |
| Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | MIB238 | | |
| Zio XT for detecting cardiac arrhythmias | HTG562 | | |
| Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer | TA660 | | |
| Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | TA661 | | |
| Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) | TA662 | | |
| QuickChange Incontinence Wrap for urinary incontinence in men | MIB237 | | |
| Acute coronary syndromes | NG185 | | |
| Drug-eluting stents for the treatment of coronary artery disease | TA152 | | |
| Acute coronary syndromes in adults | QS68 | | |
| Siponimod for treating secondary progressive multiple sclerosis | TA656 | | |
| Carfilzomib for previously treated multiple myeloma | TA657 | | |
| Guidance on the use of coronary artery stents | TA71 | | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma | TA658 | | |
| Galcanezumab for preventing migraine | TA659 | | |
| Swallowable gastric balloon capsule for weight loss | HTG561 | | |
| Magseed for locating impalpable breast cancer lesions | MIB236 | | |
| NPi-200 for pupillary light reflex in critical care patients | MIB235 | | |
| Human and animal bites: antimicrobial prescribing | NG184 | | |
| Dexcom G6 for real-time continuous glucose monitoring | MIB233 | | |
| Testing strategies for Lynch syndrome in people with endometrial cancer | HTG557 | | |
| Antimicrobial prescribing: imipenem with cilastatin and relebactam | ES30 | | |
| Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | HTG558 | | |
| Balloon cryoablation for squamous dysplasia of the oesophagus | HTG560 | | |
| Tegaderm CHG securement dressing for vascular access sites | MIB231 | | |
| Volanesorsen for treating familial chylomicronaemia syndrome | HST13 | | |
| Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy | TA655 | | |
| Heavy menstrual bleeding | QS47 | | |
| Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer | TA653 | | |
| Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA654 | | |
| SEM Scanner 200 for preventing pressure ulcers | HTG556 | | |
| Rheumatoid arthritis in adults: management | NG100 | | |
| Behaviour change: digital and mobile health interventions | NG183 | | |
| Pembrolizumab with axitinib for untreated advanced renal cell carcinoma | TA650 | | |
| Naldemedine for treating opioid-induced constipation | TA651 | | |
| Novii Wireless Patch System for maternal and fetal monitoring | MIB228 | | |
| Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma | TA649 | | |
| Transcranial magnetic stimulation for auditory hallucinations | HTG555 | | |
| Neuropathic pain in adults: pharmacological management in non-specialist settings | CG173 | | |
| t:slim X2 insulin pump for managing blood glucose levels in type 1 diabetes | MIB227 | | |
| Insect bites and stings: antimicrobial prescribing | NG182 | | |
| Dupilumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA648 | | |
| Axonics sacral neuromodulation system for treating refractory overactive bladder | HTG554 | | |
| Implantable cardiac monitors to detect atrial fibrillation after cryptogenic stroke | HTG553 | | |
| Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) | TA646 | | |
| Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) | TA647 | | |
| Helge for detecting haemolysis | MIB225 | | |
| Community pharmacies: promoting health and wellbeing | QS196 | | |
| Faltering growth | QS197 | | |
| High-sensitivity troponin tests for the early rule out of NSTEMI | HTG552 | | |
| FebriDx for C-reactive protein and myxovirus resistance protein A testing | MIB224 | | |
| Anaphylaxis: assessment and referral after emergency treatment | CG134 | | |
| Perioperative care in adults | NG180 | | |
| Rehabilitation for adults with complex psychosis | NG181 | | |
| Surgical site infections: prevention and treatment | NG125 | | |
| Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer | TA643 | | |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma | TA641 | | |
| Gilteritinib for treating relapsed or refractory acute myeloid leukaemia | TA642 | | |
| Deep brain stimulation for refractory epilepsy in adults | HTG550 | | |
| Implanted vagus nerve stimulation for treatment-resistant depression | HTG551 | | |
| pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms | MIB222 | | |
| Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome | MIB223 | | |
| Healthy.io test for home testing of urine albumin to creatinine ratio | MIB221 | | |
| Decision making and mental capacity | QS194 | | |
| Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant | TA640 | | |
| Transcranial magnetic stimulation for obsessive-compulsive disorder | HTG548 | | |
| Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease | HTG549 | | |
| Renal and ureteric stones | QS195 | | |
| Artificial iris insertion for acquired aniridia | HTG546 | | |
| Artificial iris insertion for congenital aniridia | HTG547 | | |
| Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis | ES29 | | |
| Specialist neonatal respiratory care for babies born preterm | QS193 | | |
| CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic | MIB219 | | |
| Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer | TA638 | | |
| Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer | TA639 | | |
| Ranibizumab for treating diabetic retinopathy (terminated appraisal) | TA637 | | |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA634 | | |
| Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) | TA635 | | |
| Eculizumab for treating refractory myasthenia gravis (terminated appraisal) | TA636 | | |
| Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA626 | | |
| Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia | HTG545 | | |
| MolecuLight i:X for wound imaging | MIB212 | | |
| Actim Pancreatitis for diagnosing acute pancreatitis | MIB218 | | |
| Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) | HTG544 | | |
| Ustekinumab for treating moderately to severely active ulcerative colitis | TA633 | | |
| Generalised anxiety disorder and panic disorder in adults: management | CG113 | | |
| Archimedes for biopsy of suspected lung cancer | MIB211 | | |
| Intravenous fluid therapy in children and young people in hospital | NG29 | | |
| Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | | |
| Joint replacement (primary): hip, knee and shoulder | NG157 | | |
| Larotrectinib for treating NTRK fusion-positive solid tumours | TA630 | | |
| Cytokine adsorption devices for treating respiratory failure in people with COVID-19 | MIB217 | | |
| Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer | TA628 | | |
| Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab | TA629 | | |
| Lifelight First for monitoring vital signs | MIB213 | | |
| PneuX to prevent ventilator-associated pneumonia | HTG543 | | |
| Lenalidomide with rituximab for previously treated follicular lymphoma | TA627 | | |
| Abdominal aortic aneurysm: diagnosis and management | NG156 | | |
| Artificial intelligence for analysing CT brain scans | MIB207 | | |
| NATROX oxygen wound therapy for managing diabetic foot ulcers and complex or chronic non-healing wounds | MIB208 | | |
| TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation | MIB210 | | |
| Tinnitus: assessment and management | NG155 | | |
| Cor-Knot for tying suture knots in valve surgery | MIB206 | | |
| Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) | TA625 | | |
| Bilateral cervicosacropexy (CESA) or vaginosacropexy (VASA) using mesh for pelvic organ prolapse | HTG539 | | |
| Cyanoacrylate glue occlusion for varicose veins | HTG540 | | |
| MRI-guided laser interstitial thermal therapy for drug-resistant epilepsy | HTG541 | | |
| Selective internal radiation therapy for unresectable colorectal metastases in the liver | HTG542 | | |
| Intrapartum care: existing medical conditions and obstetric complications | QS192 | | |
| Neonatal parenteral nutrition | NG154 | | |
| Impetigo: antimicrobial prescribing | NG153 | | |
| SepsiTest assay for rapidly identifying bloodstream bacteria and fungi | HTG400 | | |
| Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis | TA624 | | |
| National Early Warning Score systems that alert to deteriorating adult patients in hospital | MIB205 | | |
| Patiromer for treating hyperkalaemia | TA623 | | |
| Antenatal and postnatal mental health: clinical management and service guidance | CG192 | | |
| Leg ulcer infection: antimicrobial prescribing | NG152 | | |
| Episcissors-60 for mediolateral episiotomy | HTG538 | | |
| Cerebral palsy in adults | QS191 | | |
| Fetoscopic prenatal repair for open neural tube defects in the fetus | HTG536 | | |
| Open prenatal repair for open neural tube defects in the fetus | HTG537 | | |
| Supporting adult carers | NG150 | | |
| Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues | HTG535 | | |
| Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C | HTG385 | | |
| Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal) | TA618 | | |
| Flu vaccination: increasing uptake | QS190 | | |
| Rheumatoid arthritis in over 16s | QS33 | | |
| Indoor air quality at home | NG149 | | |
| Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | TA617 | | |
| Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia | ES22 | | |
| Cannabidiol with clobazam for treating seizures associated with Dravet syndrome | TA614 | | |
| Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome | TA615 | | |
| Balloon dilation for chronic eustachian tube dysfunction | HTG534 | | |
| LQD Spray for treating acute and chronic wounds | MIB202 | | |
| PulmoVista 500 for monitoring ventilation in critical care | MIB203 | | |
| Lung cancer in adults | QS17 | | |
| eXroid for internal haemorrhoids | MIB201 | | |
| PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection | MIB200 | | |
| Optowire for measuring fractional flow reserve | MIB199 | | |
| gammaCore for cluster headache | HTG533 | | |
| Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 | HST12 | | |
| Diverticular disease: diagnosis and management | NG147 | | |
| Irreversible electroporation for primary liver cancer | HTG532 | | |
| AmnioSense for unexplained vaginal wetness in pregnancy | MIB198 | | |
| Antimicrobial prescribing: meropenem with vaborbactam | ES21 | | |
| Workplace health: long-term sickness absence and capability to work | NG146 | | |
| Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | | |
| Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast | HTG530 | | |
| Rapid tests for group A streptococcal infections in people with a sore throat | HTG531 | | |
| Pentosan polysulfate sodium for treating bladder pain syndrome | TA610 | | |
| Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) | TA608 | | |
| Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) | TA609 | | |
| Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management | CG184 | | |
| Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease | TA607 | | |
| End of life care for adults: service delivery | NG142 | | |
| Lanadelumab for preventing recurrent attacks of hereditary angioedema | TA606 | | |
| Midcarpal hemiarthroplasty for wrist arthritis | HTG529 | | |
| superDimension Navigation System to help diagnostic sampling of peripheral lung lesions | MIB194 | | |
| MR-proADM test for use with clinical deterioration scores in cases of suspected infection | MIB195 | | |
| Diabetic foot problems: prevention and management | NG19 | | |
| Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations | HST11 | | |
| Gastro-oesophageal reflux disease in children and young people: diagnosis and management | NG1 | | |
| Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea | TA605 | | |
| EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing | HTG296 | | |
| Familial hypercholesterolaemia: identification and management | CG71 | | |
| Idelalisib for treating refractory follicular lymphoma | TA604 | | |
| Cellulitis and erysipelas: antimicrobial prescribing | NG141 | | |
| Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA602 | | |
| Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal) | TA603 | | |
| High-intensity focused ultrasound for glaucoma | HTG527 | | |
| Bioprosthetic plug insertion for anal fistula | HTG528 | | |
| Tegaderm CHG securement dressing for vascular access sites in critically ill adults | HTG379 | | |
| Attention deficit hyperactivity disorder: diagnosis and management | NG87 | | |
| Implant insertion for prominent ears | HTG526 | | |
| InterDry for intertrigo | MIB192 | | |
| Suicide prevention | QS189 | | |
| SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea | MIB190 | | |
| Multiple pregnancy: twin and triplet pregnancies | QS46 | | |
| Benralizumab for treating severe eosinophilic asthma | TA565 | | |
| Risankizumab for treating moderate to severe plaque psoriasis | TA596 | | |
| Coexisting severe mental illness and substance misuse | QS188 | | |
| Patisiran for treating hereditary transthyretin amyloidosis | HST10 | | |
| Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer | TA595 | | |
| Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms | HTG524 | | |
| Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism | NG89 | | |
| Alcohol interventions in secondary and further education | NG135 | | |
| PICO negative pressure wound dressings for closed surgical incisions | HTG509 | | |
| Preterm labour and birth | QS135 | | |
| Service user experience in adult mental health services | QS14 | | |
| Patient experience in adult NHS services | QS15 | | |
| Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | | |
| Letermovir for preventing cytomegalovirus disease after a stem cell transplant | TA591 | | |
| Chronic obstructive pulmonary disease in over 16s: diagnosis and management | NG115 | | |
| End of life care for infants, children and young people with life-limiting conditions: planning and management | NG61 | | |
| Learning disability: behaviour that challenges | QS101 | | |
| Learning disability: care and support of people growing older | QS187 | | |
| Nusinersen for treating spinal muscular atrophy | TA588 | | |
| Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity | TA589 | | |
| Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer | HTG522 | | |
| Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids | HTG523 | | |
| Motor neurone disease: assessment and management | NG42 | | |
| Hypertension in pregnancy | QS35 | | |
| HemaClear for bloodless surgical field during limb surgery | MIB187 | | |
| Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis | HTG521 | | |
| Hearing loss in adults | QS185 | | |
| Lyme disease | QS186 | | |
| Bisphosphonates for treating osteoporosis | TA464 | | |
| Long-acting reversible contraception | CG30 | | |
| Dementia | QS184 | | |
| The OPTIMIZER smart system for managing heart failure | MIB186 | | |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality | TA322 | | |
| Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies | TA171 | | |
| Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib | TA586 | | |
| Lenalidomide plus dexamethasone for previously untreated multiple myeloma | TA587 | | |
| Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction | HTG518 | | |
| Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia | HTG519 | | |
| Cardiac contractility modulation device implantation for heart failure | HTG520 | | |
| Depression in children and young people: identification and management | NG134 | | |
| Urinary incontinence and pelvic organ prolapse in women: management | NG123 | | |
| Ambu aScope4 Broncho for use in unexpected difficult airways | HTG312 | | |
| Ocrelizumab for treating primary progressive multiple sclerosis | TA585 | | |
| Percutaneous insertion of a cerebral protection device to prevent cerebral embolism during TAVI | HTG515 | | |
| Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg | HTG516 | | |
| Bronchoscopic thermal vapour ablation for upper-lobe emphysema | HTG517 | | |
| Endocuff Vision for assisting visualisation during colonoscopy | HTG514 | | |
| Physical activity: encouraging activity in the community | QS183 | | |
| Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes | TA583 | | |
| Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer | TA584 | | |
| The Sherlock 3CG Tip Confirmation System for placement of peripherally inserted central catheters | HTG368 | | |
| Percutaneous mitral valve leaflet repair for mitral regurgitation | HTG513 | | |
| Therapeutic hypothermia for acute ischaemic stroke | HTG511 | | |
| Collagen paste for closing an anal fistula | HTG512 | | |
| Hyperparathyroidism (primary): diagnosis, assessment and initial management | NG132 | | |
| Inotersen for treating hereditary transthyretin amyloidosis | HST9 | | |
| Enzalutamide for hormone-relapsed non-metastatic prostate cancer | TA580 | | |
| Curos for preventing infections when using needleless connectors | HTG510 | | |
| Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care | HTG508 | | |
| DuraGraft for preserving vascular grafts | MIB184 | | |
| Ulcerative colitis: management | NG130 | | |
| Crohn's disease: management | NG129 | | |
| Intrapartum care for women with existing medical conditions or obstetric complications and their babies | NG121 | | |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | TA577 | | |
| Certolizumab pegol for treating moderate to severe plaque psoriasis | TA574 | | |
| Tildrakizumab for treating moderate to severe plaque psoriasis | TA575 | | |
| Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) | TA576 | | |
| Endoscopic ablation for an anal fistula | HTG506 | | |
| Endoscopic ablation for a pilonidal sinus | HTG507 | | |
| ADXBLADDER for detecting bladder cancer | MIB180 | | |
| Specialist neonatal respiratory care for babies born preterm | NG124 | | |
| Narrow band imaging for Barrett's oesophagus | MIB179 | | |
| Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes | TA572 | | |
| The Debrisoft monofilament debridement pad for use in acute or chronic wounds | HTG334 | | |
| Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | | |
| Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) | TA570 | | |
| Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib | TA571 | | |
| Kendall DL for ECG monitoring in people having cardiac surgery | MIB177 | | |
| Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | | |
| Radially emitting laser fibre treatment of an anal fistula | HTG505 | | |
| Cochlear implants for children and adults with severe to profound deafness | TA566 | | |
| CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease | MIB174 | | |
| Prevena incision management system for closed surgical incisions | MIB173 | | |
| Air pollution: outdoor air quality and health | QS181 | | |
| People's experience using adult social care services | QS182 | | |
| Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA563 | | |
| Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia | TA561 | | |
| Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | TA562 | | |
| High-intensity focused ultrasound for symptomatic benign thyroid nodules | HTG504 | | |
| Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) | TA560 | | |
| Barnett Continent Intestinal Reservoir (modified continent ileostomy) to restore continence after colon and rectum removal | HTG503 | | |
| Opioid dependence: buprenorphine prolonged-release injection (Buvidal) | ES19 | | |
| Serious eye disorders | QS180 | | |
| Child abuse and neglect | QS179 | | |
| Axumin for functional imaging of prostate cancer recurrence | MIB172 | | |
| Cough (acute): antimicrobial prescribing | NG120 | | |
| Sexual health | QS178 | | |
| StoneChecker for kidney stone evaluation | MIB171 | | |
| Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer | HTG499 | | |
| Laparoscopic cerclage for cervical incompetence to prevent late miscarriage or preterm birth | HTG500 | | |
| Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis | HTG501 | | |
| Path Finder for freezing of gait in people with Parkinson's disease | MIB170 | | |
| Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain | HTG498 | | |
| Platelet-rich plasma injections for knee osteoarthritis | HTG497 | | |
| LiMAx system for assessing the functional capacity of the liver | MIB168 | | |
| RT300 for spinal cord injury rehabilitation | MIB169 | | |
| Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation | HTG496 | | |
| Cerebral palsy in adults | NG119 | | |
| Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers | HTG495 | | |
| Regorafenib for previously treated advanced hepatocellular carcinoma | TA555 | | |
| Darvadstrocel for treating complex perianal fistulas in Crohn's disease | TA556 | | |
| Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms | HTG287 | | |
| Renal and ureteric stones: assessment and management | NG118 | | |
| Pancreatic cancer | QS177 | | |
| Video laryngoscopes to help intubation in people with difficult airways | MIB167 | | |
| Lenvatinib for untreated advanced hepatocellular carcinoma | TA551 | | |
| Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia | TA552 | | |
| Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults | HTG493 | | |
| Bronchial thermoplasty for severe asthma | HTG494 | | |
| Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing | NG117 | | |
| Galaxy UNYCO for temporary stabilisation of lower limb fractures | MIB166 | | |
| Oesophago-gastric cancer | QS176 | | |
| Vandetanib for treating medullary thyroid cancer | TA550 | | |
| Post-traumatic stress disorder | NG116 | | |
| Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing | NG114 | | |
| Decitabine for untreated acute myeloid leukaemia (terminated appraisal) | TA548 | | |
| Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) | TA549 | | |
| Tofacitinib for moderately to severely active ulcerative colitis | TA547 | | |
| Transcranial MRI-guided focused ultrasound thalamotomy for neuropathic pain | HTG491 | | |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | HTG492 | | |
| Urinary tract infection (catheter-associated): antimicrobial prescribing | NG113 | | |
| Padeliporfin for untreated localised prostate cancer | TA546 | | |
| Gemtuzumab ozogamicin for untreated acute myeloid leukaemia | TA545 | | |
| Subcutaneous automated low-flow pump implantation for refractory ascites caused by cirrhosis | HTG490 | | |
| Urinary tract infection (lower): antimicrobial prescribing | NG109 | | |
| Prostatitis (acute): antimicrobial prescribing | NG110 | | |
| Pyelonephritis (acute): antimicrobial prescribing | NG111 | | |
| Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma | HTG489 | | |
| Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children | MIB163 | | |
| Eltrombopag for treating chronic immune thrombocytopenia | TA293 | | |
| Romiplostim for the treatment of chronic immune thrombocytopenia | TA221 | | |
| Myeloma: diagnosis and management | NG35 | | |
| Lyme disease | NG95 | | |
| Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | TA544 | | |
| Renal replacement therapy and conservative management | NG107 | | |
| Decision-making and mental capacity | NG108 | | |
| Renal replacement therapy services for adults | QS72 | | |
| Cabozantinib for untreated advanced renal cell carcinoma | TA542 | | |
| Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | | |
| myAIRVO2 for the treatment of chronic obstructive pulmonary disease | MIB161 | | |
| E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta | HTG326 | | |
| OxyMask for delivering oxygen therapy | MIB160 | | |
| Eating disorders | QS175 | | |
| Asthma | QS25 | | |
| Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia | TA541 | | |
| Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer | HTG487 | | |
| The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs | MIB159 | | |
| Preventing suicide in community and custodial settings | NG105 | | |
| Emergency and acute medical care in over 16s | QS174 | | |
| Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours | TA539 | | |
| Leadless cardiac pacemaker implantation for bradyarrhythmias | HTG484 | | |
| Superior rectal artery embolisation for haemorrhoids | HTG485 | | |
| Neon EEG electrode for EEG monitoring in newborns | MIB155 | | |
| AlignRT in breast cancer radiotherapy | MIB157 | | |
| Flu vaccination: increasing uptake | NG103 | | |
| Dinutuximab beta for treating neuroblastoma | TA538 | | |
| Sutureless aortic valve replacement for aortic stenosis | HTG483 | | |
| Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG482 | | |
| Intermediate care including reablement | QS173 | | |
| Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine | TA535 | | |
| Alectinib for untreated ALK-positive advanced non-small-cell lung cancer | TA536 | | |
| Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | | |
| Endometriosis | QS172 | | |
| Community pharmacies: promoting health and wellbeing | NG102 | | |
| Dupilumab for treating moderate to severe atopic dermatitis | TA534 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing | HTG479 | | |
| Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing | HTG480 | | |
| Low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures | HTG481 | | |
| Mechanical thrombectomy devices for acute ischaemic stroke | MIB153 | | |
| Remote ECG interpretation consultancy services for cardiovascular disease | MIB152 | | |
| Ocrelizumab for treating relapsing–remitting multiple sclerosis | TA533 | | |
| Superior capsular augmentation for massive rotator cuff tears | HTG477 | | |
| Transaxial interbody lumbosacral fusion for severe chronic low back pain | HTG478 | | |
| Medicines management for people receiving social care in the community | QS171 | | |
| Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer | TA531 | | |
| Airglove air warming system for venous access | MIB151 | | |
| Biomarker tests to help diagnose preterm labour in women with intact membranes | HTG476 | | |
| Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy | TA530 | | |
| Spondyloarthritis | QS170 | | |
| Beta interferons and glatiramer acetate for treating multiple sclerosis | TA527 | | |
| Dementia: assessment, management and support for people living with dementia and their carers | NG97 | | |
| Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease | TA217 | | |
| Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor | HTG474 | | |
| Laparoscopic ventral mesh rectopexy for internal rectal prolapse | HTG475 | | |
| ORA G3 to measure corneal hysteresis | MIB150 | | |
| Arsenic trioxide for treating acute promyelocytic leukaemia | TA526 | | |
| Guselkumab for treating moderate to severe plaque psoriasis | TA521 | | |
| Midostaurin for untreated acute myeloid leukaemia | TA523 | | |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma | TA524 | | |
| Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA525 | | |
| Intranasal phototherapy for allergic rhinitis | HTG473 | | |
| Cancer of the upper aerodigestive tract: assessment and management in people aged 16 or over | NG36 | | |
| VIDAvision for lung volume analysis in emphysema | MIB148 | | |
| Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy | HTG472 | | |
| Cystic fibrosis | QS168 | | |
| Developmental follow-up of children and young people born preterm | QS169 | | |
| AlignRT for intracranial stereotactic radiosurgery | MIB147 | | |
| Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy | TA520 | | |
| Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups | QS167 | | |
| Percutaneous balloon valvuloplasty for fetal critical aortic stenosis | HTG471 | | |
| Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I | HTG467 | | |
| Robot-assisted kidney transplant | HTG468 | | |
| Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia | HTG469 | | |
| Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma | HTG470 | | |
| Noctura 400 Sleep Mask for diabetic retinopathy and diabetic macular oedema | MIB144 | | |
| Nerve transfer to partially restore upper limb function in tetraplegia | HTG466 | | |
| Tocilizumab for treating giant cell arteritis | TA518 | | |
| ColonFlag for identifying people at risk of colorectal cancer | MIB142 | | |
| Care and support of people growing older with learning disabilities | NG96 | | |
| Drug misuse prevention | QS165 | | |
| Trauma | QS166 | | |
| Learning disabilities and behaviour that challenges: service design and delivery | NG93 | | |
| Emergency and acute medical care in over 16s: service delivery and organisation | NG94 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen | TA515 | | |
| Cabozantinib for treating medullary thyroid cancer | TA516 | | |
| Physical activity and the environment | NG90 | | |
| Brodalumab for treating moderate to severe plaque psoriasis | TA511 | | |
| Tivozanib for treating advanced renal cell carcinoma | TA512 | | |
| Obinutuzumab for untreated advanced follicular lymphoma | TA513 | | |
| Attention deficit hyperactivity disorder | QS39 | | |
| Mosaicplasty for symptomatic articular cartilage defects of the knee | HTG463 | | |
| Laparoscopic mesh pectopexy for apical prolapse of the uterus or vagina | HTG464 | | |
| Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee | TA508 | | |
| Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | | |
| Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C | TA507 | | |
| People's experience in adult social care services: improving the experience of care and support for people using adult social care services | NG86 | | |
| Coban 2 for venous leg ulcers | MIB140 | | |
| Aortic valve reconstruction with processed bovine pericardium | HTG461 | | |
| Mental health of adults in contact with the criminal justice system | QS163 | | |
| Parkinson's disease | QS164 | | |
| Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency | HST7 | | |
| Atrial fibrillation | QS93 | | |
| Pancreatic cancer in adults: diagnosis and management | NG85 | | |
| Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women | TA160 | | |
| Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women | TA161 | | |
| Pirfenidone for treating idiopathic pulmonary fibrosis | TA504 | | |
| Intrabeam radiotherapy system for adjuvant treatment of early breast cancer | TA501 | | |
| Ibrutinib for treating relapsed or refractory mantle cell lymphoma | TA502 | | |
| Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer | TA503 | | |
| EpiFix for chronic wounds | MIB139 | | |
| Minimally invasive percutaneous nephrolitholapaxy medium (MIP-M) for removing kidney stones | MIB138 | | |
| Sore throat (acute): antimicrobial prescribing | NG84 | | |
| Ceritinib for untreated ALK-positive non-small-cell lung cancer | TA500 | | |
| Lenvatinib with everolimus for previously treated advanced renal cell carcinoma | TA498 | | |
| Glecaprevir–pibrentasvir for treating chronic hepatitis C | TA499 | | |
| Age-related macular degeneration | NG82 | | |
| Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer | MIB137 | | |
| MammaTyper in vitro diagnostic test for determining breast cancer subtypes | MIB135 | | |
| TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum | MIB134 | | |
| Golimumab for treating active non-radiographic axial spondyloarthritis | TA497 | | |
| Next-generation sequencing panel for solid tumour cancers in children | MIB133 | | |
| Autism spectrum disorder in under 19s: recognition, referral and diagnosis | CG128 | | |
| Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA495 | | |
| Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer | TA496 | | |
| Endobronchial valve insertion to reduce lung volume in emphysema | HTG457 | | |
| Transcutaneous microwave ablation for severe primary axillary hyperhidrosis | HTG458 | | |
| Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure | HTG459 | | |
| Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death | HTG460 | | |
| Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system) | HTG353 | | |
| Transvaginal mesh repair of anterior or posterior vaginal wall prolapse | HTG456 | | |
| Naltrexone–bupropion for managing overweight and obesity | TA494 | | |
| Suspected cancer | QS124 | | |
| Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease | MIB132 | | |
| Vismodegib for treating basal cell carcinoma | TA489 | | |
| Processed nerve allografts to repair peripheral nerve discontinuities | HTG454 | | |
| Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea | HTG455 | | |
| Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | | |
| Tests in secondary care to identify people at high risk of ovarian cancer | HTG453 | | |
| Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours | TA488 | | |
| Total distal radioulnar joint replacement for symptomatic joint instability or arthritis | HTG451 | | |
| Extracranial to intracranial bypass for intracranial atherosclerosis | HTG452 | | |
| HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer | MIB128 | | |
| Familial hypercholesterolaemia | QS41 | | |
| Aflibercept for treating choroidal neovascularisation | TA486 | | |
| Sarilumab for moderate to severe rheumatoid arthritis | TA485 | | |
| Radiation dose monitoring software for medical imaging with ionising radiation | MIB127 | | |
| Sinusitis (acute): antimicrobial prescribing | NG79 | | |
| Cataracts in adults: management | NG77 | | |
| Cystic fibrosis: diagnosis and management | NG78 | | |
| Hepatitis B (chronic): diagnosis and management | CG165 | | |
| PleuraFlow Active Clearance Technology for maintaining chest tube patency | MIB125 | | |
| Immunosuppressive therapy for kidney transplant in adults | TA481 | | |
| Immunosuppressive therapy for kidney transplant in children and young people | TA482 | | |
| Tofacitinib for moderate to severe rheumatoid arthritis | TA480 | | |
| Cerebral palsy in children and young people | QS162 | | |
| Child abuse and neglect | NG76 | | |
| Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee | TA477 | | |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma | TA478 | | |
| Reslizumab for treating severe eosinophilic asthma | TA479 | | |
| Thora-3Di for assessing asthma in children | MIB122 | | |
| Memokath-028, 044 and 045 stents for urethral obstruction | MIB123 | | |
| FreeStyle Libre for glucose monitoring | MIB110 | | |
| Faltering growth: recognition and management of faltering growth in children | NG75 | | |
| Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease | HTG450 | | |
| Cetuximab and panitumumab for previously untreated metastatic colorectal cancer | TA439 | | |
| Intermediate care including reablement | NG74 | | |
| Caris Molecular Intelligence for guiding cancer treatment | MIB120 | | |
| Type 2 diabetes: prevention in people at high risk | PH38 | | |
| Aptiva for painful diabetic neuropathy | MIB119 | | |
| High-intensity focused ultrasound for symptomatic breast fibroadenoma | HTG449 | | |
| Ab externo canaloplasty for primary open-angle glaucoma | HTG448 | | |
| Transition between inpatient mental health settings and community or care home settings | QS159 | | |
| End of life care for infants, children and young people | QS160 | | |
| Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy | TA428 | | |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab | TA357 | | |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab | TA366 | | |
| Physical health of people in prisons | QS156 | | |
| HIV testing: encouraging uptake | QS157 | | |
| Rehabilitation after critical illness in adults | QS158 | | |
| Fertility problems: assessment and treatment | CG156 | | |
| Sorafenib for treating advanced hepatocellular carcinoma | TA474 | | |
| Dimethyl fumarate for treating moderate to severe plaque psoriasis | TA475 | | |
| Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer | TA476 | | |
| Psoriasis: assessment and management | CG153 | | |
| Fungitell for antifungal treatment stratification | MIB118 | | |
| Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck | TA473 | | |
| Vitamin D: supplement use in specific population groups | PH56 | | |
| Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) | TA468 | | |
| Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) | TA469 | | |
| Radiofrequency treatment for haemorrhoids | HTG447 | | |
| Holoclar for treating limbal stem cell deficiency after eye burns | TA467 | | |
| Pemetrexed for the maintenance treatment of non-small-cell lung cancer | TA190 | | |
| Biopatch for venous or arterial catheter sites | MIB117 | | |
| Developmental follow-up of children and young people born preterm | NG72 | | |
| Cabozantinib for previously treated advanced renal cell carcinoma | TA463 | | |
| Baricitinib for moderate to severe rheumatoid arthritis | TA466 | | |
| Urethrotech UCD for difficult or failed catheterisation | MIB116 | | |
| moorLDI2-BI: a laser doppler blood flow imager for burn wound assessment | HTG257 | | |
| Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition | CG32 | | |
| VEST external stent for coronary artery bypass grafts | MIB115 | | |
| Low back pain and sciatica in over 16s | QS155 | | |
| Chronic kidney disease in adults | QS5 | | |
| Adalimumab and dexamethasone for treating non-infectious uveitis | TA460 | | |
| Roflumilast for treating chronic obstructive pulmonary disease | TA461 | | |
| Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma | TA462 | | |
| Transcatheter aortic valve implantation for aortic stenosis | HTG446 | | |
| Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry | MIB113 | | |
| Parkinson's disease in adults | NG71 | | |
| Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest | MIB112 | | |
| Constipation in children and young people: diagnosis and management | CG99 | | |
| Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people | TA455 | | |
| Ustekinumab for moderately to severely active Crohn's disease after previous treatment | TA456 | | |
| New generation cardiac CT scanners (Aquilion ONE, Brilliance iCT, Discovery CT750 HD and Somatom Definition Flash) for cardiac imaging in people with suspected or known coronary artery disease in whom imaging is difficult with earlier generation CT scanners | HTG281 | | |
| Aquilion PRIME CT scanner for imaging coronary artery disease in adults in whom imaging is difficult | MIB53 | | |
| Somatom Definition Edge CT scanner for imaging coronary artery disease in adults in whom imaging is difficult | MIB54 | | |
| Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) | TA452 | | |
| Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) | TA453 | | |
| Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA454 | | |
| L-Dex U400 for lymphoedema after breast cancer treatment | MIB111 | | |
| Air pollution: outdoor air quality and health | NG70 | | |
| Multimorbidity | QS153 | | |
| Violent and aggressive behaviours in people with mental health problems | QS154 | | |
| Liver disease | QS152 | | |
| Eliglustat for treating type 1 Gaucher disease | HST5 | | |
| Etelcalcetide for treating secondary hyperparathyroidism | TA448 | | |
| Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease | TA449 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia | TA450 | | |
| Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia | TA451 | | |
| Infracoccygeal sacropexy using mesh to repair vaginal vault prolapse | HTG442 | | |
| Infracoccygeal sacropexy using mesh to repair uterine prolapse | HTG443 | | |
| Sacrocolpopexy using mesh to repair vaginal vault prolapse | HTG444 | | |
| Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse | HTG445 | | |
| Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis | HTG441 | | |
| RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease | MIB109 | | |
| Neo Pedicle Screw System for spinal fusion surgery | MIB108 | | |
| Oral health in care homes | QS151 | | |
| SecurAcath for securing cerebrospinal fluid catheters | MIB107 | | |
| Spondyloarthritis in over 16s: diagnosis and management | NG65 | | |
| Haematological cancers | QS150 | | |
| Bindex for investigating suspected osteoporosis | MIB106 | | |
| Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) | TA444 | | |
| Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | | |
| Endoscopic full thickness removal of non-lifting colonic polyps | HTG439 | | |
| Idiopathic pulmonary fibrosis in adults: diagnosis and management | CG163 | | |
| Permacol for treating anal fistulae | MIB105 | | |
| NaviCam for diagnosing gastrointestinal tract conditions | MIB104 | | |
| Virtual chromoendoscopy to assess colorectal polyps during colonoscopy | HTG438 | | |
| Intravenous fluid therapy in adults in hospital | CG174 | | |
| Hemosep for cell salvage | MIB103 | | |
| Irreversible electroporation for treating pancreatic cancer | HTG437 | | |
| Osteoporosis | QS149 | | |
| Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine | TA440 | | |
| Ixekizumab for treating moderate to severe plaque psoriasis | TA442 | | |
| Obeticholic acid for treating primary biliary cholangitis | TA443 | | |
| VAAFT for treating anal fistulae | MIB102 | | |
| Antisocial behaviour and conduct disorders in children and young people: recognition and management | CG158 | | |
| Alcohol-use disorders: diagnosis and management of physical complications | CG100 | | |
| Sexually transmitted infections: condom distribution schemes | NG68 | | |
| Minimally invasive sacroiliac joint fusion surgery for chronic sacroiliac pain | HTG436 | | |
| Irritable bowel syndrome in adults: diagnosis and management | CG61 | | |
| Managing medicines for adults receiving social care in the community | NG67 | | |
| Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal) | TA240 | | |
| Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) | TA438 | | |
| Mitochondrial disorders in children: Co-enzyme Q10 | ES11 | | |
| Mollii suit for spasticity | MIB100 | | |
| Bair Hugger for measuring core temperature during perioperative care | MIB99 | | |
| Patient group directions | MPG2 | | |
| Elotuzumab for previously treated multiple myeloma (terminated appraisal) | TA434 | | |
| Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) | TA435 | | |
| Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) | TA436 | | |
| Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) | TA437 | | |
| Extraurethral (non-circumferential) retropubic adjustable compression devices for stress urinary incontinence in women | HTG434 | | |
| Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse | HTG435 | | |
| Hyperhidrosis: oxybutynin | ES10 | | |
| Mental health of adults in contact with the criminal justice system | NG66 | | |
| Narcolepsy with or without cataplexy in adults: pitolisant | ES8 | | |
| Skin involvement in systemic sclerosis: rituximab | ES7 | | |
| TopClosure Tension Relief System for wound closure | MIB97 | | |
| SimpliCT laser-guided needle placement in interventional radiology | MIB98 | | |
| Head and neck cancer | QS146 | | |
| Healthy workplaces: improving employee mental and physical health and wellbeing | QS147 | | |
| Community engagement: improving health and wellbeing | QS148 | | |
| Ustekinumab for treating active psoriatic arthritis | TA340 | | |
| Ustekinumab for treating moderate to severe plaque psoriasis | TA180 | | |
| Care of dying adults in the last days of life | QS144 | | |
| Intrapartum care | QS105 | | |
| Molecular testing strategies for Lynch syndrome in people with colorectal cancer | HTG430 | | |
| Migalastat for treating Fabry disease | HST4 | | |
| Drug misuse prevention: targeted interventions | NG64 | | |
| Everolimus for advanced renal cell carcinoma after previous treatment | TA432 | | |
| Apremilast for treating active psoriatic arthritis | TA433 | | |
| Lateral interbody fusion in the lumbar spine for low back pain | HTG431 | | |
| Trabecular stent bypass microsurgery for open-angle glaucoma | HTG432 | | |
| Healthcare-associated infections: prevention and control in primary and community care | CG139 | | |
| Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide | ES5 | | |
| Smart One for measuring lung function | MIB96 | | |
| U-Drain for people needing night drainage of urine or dialysis fluid | MIB95 | | |
| Menopause | QS143 | | |
| HumiGard for preventing inadvertent perioperative hypothermia | HTG428 | | |
| Osteoporosis: assessing the risk of fragility fracture | CG146 | | |
| eazyplex SuperBug kits for detecting carbapenemase-producing organisms | MIB94 | | |
| Stable angina | QS21 | | |
| Cerebral palsy in under 25s: assessment and management | NG62 | | |
| Antimicrobial stewardship: changing risk-related behaviours in the general population | NG63 | | |
| Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation | TA429 | | |
| Sofosbuvir–velpatasvir for treating chronic hepatitis C | TA430 | | |
| Boston Keratoprosthesis Type I for corneal blindness | MIB91 | | |
| CentriMag for heart failure | MIB92 | | |
| Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis | MIB93 | | |
| Refractory extrapulmonary sarcoidosis: infliximab | ES4 | | |
| Smartinhaler for asthma | MIB90 | | |
| Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib | TA427 | | |
| Learning disability: identifying and managing mental health problems | QS142 | | |
| Tuberculosis | QS141 | | |
| Organ donation for transplantation: improving donor identification and consent rates for deceased organ donation | CG135 | | |
| Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens | TA423 | | |
| Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | | |
| Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia | TA425 | | |
| Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia | TA426 | | |
| Everolimus with exemestane for treating advanced breast cancer after endocrine therapy | TA421 | | |
| Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA422 | | |
| Extracorporeal shockwave therapy for Achilles tendinopathy | HTG426 | | |
| Radiation therapy for early Dupuytren's disease | HTG427 | | |
| Pulmonary sarcoidosis: infliximab | ES2 | | |
| Blood transfusion | QS138 | | |
| Oral health promotion in the community | QS139 | | |
| Hypothermia: prevention and management in adults having surgery | CG65 | | |
| Ticagrelor for preventing atherothrombotic events after myocardial infarction | TA420 | | |
| Epiduroscopic lumbar discectomy through the sacral hiatus for sciatica | HTG425 | | |
| XprESS multi sinus dilation system for treating chronic sinusitis | HTG424 | | |
| CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes | MIB48 | | |
| Mental wellbeing and independence for older people | QS137 | | |
| Transition between inpatient hospital settings and community or care home settings for adults with social care needs | QS136 | | |
| Recent-onset chest pain of suspected cardiac origin: assessment and diagnosis | CG95 | | |
| Coexisting severe mental illness and substance misuse: community health and social care services | NG58 | | |
| Spasticity in under 19s: management | CG145 | | |
| OCS Heart system for heart transplant | MIB86 | | |
| CytoSorb therapy for sepsis | MIB87 | | |
| Sternal Talon for sternal closure in cardiothoracic surgery | MIB88 | | |
| Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions | MIB89 | | |
| Nivolumab for previously treated advanced renal cell carcinoma | TA417 | | |
| Dapagliflozin in triple therapy for treating type 2 diabetes | TA418 | | |
| Apremilast for treating moderate to severe plaque psoriasis | TA419 | | |
| Dapagliflozin in combination therapy for treating type 2 diabetes | TA288 | | |
| Endoscopic transluminal pancreatic necrosectomy | HTG421 | | |
| Percutaneous insertion of craniocaudal expandable implants for vertebral compression fracture | HTG422 | | |
| Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity | HTG423 | | |
| High-throughput non-invasive prenatal testing for fetal RHD genotype | HTG420 | | |
| Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab | ES1 | | |
| Physical health of people in prison | NG57 | | |
| Psychosis and schizophrenia in children and young people: recognition and management | CG155 | | |
| Needle-free arterial non-injectable connector | MIB85 | | |
| Elbasvir–grazoprevir for treating chronic hepatitis C | TA413 | | |
| Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | TA414 | | |
| Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor | TA415 | | |
| Coeliac disease | QS134 | | |
| Children's attachment | QS133 | | |
| Single-incision short sling mesh insertion for stress urinary incontinence in women | HTG419 | | |
| Woundchek Protease Status for assessing elevated protease status in chronic wounds | MIB83 | | |
| Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion | TA409 | | |
| Talimogene laherparepvec for treating unresectable metastatic melanoma | TA410 | | |
| Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer | TA411 | | |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases | TA412 | | |
| Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer | TA406 | | |
| Pegaspargase for treating acute lymphoblastic leukaemia | TA408 | | |
| Secukinumab for treating active ankylosing spondylitis | TA407 | | |
| Miniature lens system implantation for advanced age-related macular degeneration | HTG418 | | |
| Multimorbidity: clinical assessment and management | NG56 | | |
| Intravenous fluid therapy in children and young people in hospital | QS131 | | |
| Social care for older people with multiple long-term conditions | QS132 | | |
| Harmful sexual behaviour among children and young people | NG55 | | |
| QuikRead go for C-reactive protein testing in primary care | MIB78 | | |
| FLEXISEQ for osteoarthritis | MIB80 | | |
| Alere Afinion CRP for C-reactive protein testing in primary care | MIB81 | | |
| Mental health problems in people with learning disabilities: prevention, assessment and management | NG54 | | |
| Contraception | QS129 | | |
| Transition between inpatient mental health settings and community or care home settings | NG53 | | |
| Stable angina: management | CG126 | | |
| Acute upper gastrointestinal bleeding in over 16s: management | CG141 | | |
| Axxent electronic brachytherapy system for early stage breast cancer | MIB76 | | |
| OSNA for colon cancer staging | MIB77 | | |
| Bosutinib for previously treated chronic myeloid leukaemia | TA401 | | |
| Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin | TA402 | | |
| Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel | TA391 | | |
| Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer | TA403 | | |
| Degarelix for treating advanced hormone-dependent prostate cancer | TA404 | | |
| Trifluridine–tipiracil for previously treated metastatic colorectal cancer | TA405 | | |
| Early years: promoting health and wellbeing in under 5s | QS128 | | |
| Palliative care for adults: strong opioids for pain relief | CG140 | | |
| Motor neurone disease | QS126 | | |
| Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts | TA399 | | |
| Nivolumab in combination with ipilimumab for treating advanced melanoma | TA400 | | |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated | TA387 | | |
| Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen | TA259 | | |
| Percutaneous endoscopic laser balloon pulmonary vein isolation for atrial fibrillation | HTG417 | | |
| QTUG for assessing falls risk and frailty | MIB73 | | |
| Stretta System for gastro-oesophageal reflux disease | MIB74 | | |
| Non-Hodgkin's lymphoma: diagnosis and management | NG52 | | |
| Alair bronchial thermoplasty system for adults with severe difficult to control asthma | MIB71 | | |
| Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures | CG64 | | |
| Non-alcoholic fatty liver disease (NAFLD): assessment and management | NG49 | | |
| Oral health for adults in care homes | NG48 | | |